Actively Recruiting
Value of Screening MRI Brain in Stage IV Non-small Cell Lung Cancer
Led by University Medical Center Groningen · Updated on 2024-05-23
100
Participants Needed
1
Research Sites
111 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Patients with newly diagnosed stage IV non-oncogene addicted NSCLC, who are fit for systemic treatment and don't have any symptoms of brain disease will undergo an MRI of the brain to screen for brain disease.
CONDITIONS
Official Title
Value of Screening MRI Brain in Stage IV Non-small Cell Lung Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically or cytologically confirmed stage IV metastatic NSCLC, not amenable to curative treatment.
- Fit for systemic treatment (PS 0-2) according to standard of care.
- No symptoms of brain disease assessed according to standard clinical care by the thoracic oncologist.
You will not qualify if you...
- Prior or current therapy for stage IV disease.
- Presence of oncogenic driver mutations (e.g., EGFR, ALK, ROS1, RET, MET, BRAF) with approved targeted treatments.
- Contraindications to MRI scan with contrast as per institutional standard care protocol.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University Medical Center Groningen
Groningen, Netherlands, 9713LZ
Actively Recruiting
Research Team
F
F. Bensch, MD, PhD
CONTACT
L
L.B.M. Hijmering, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
SCREENING
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here